{
  "id": 7924632,
  "title": "Celltrion’s Remsima Takes No. 1 Spot in Japan’s Infliximab Market After 11 Years",
  "url": "https://urgent.news/2026/09/17/celltrions-remsima-takes-no-1-spot-in-japans-infliximab-market-after",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-17T02:14:42.000Z",
  "source": {
    "name": "Korea IT Times",
    "slug": "korea-it-times",
    "url": "https://www.koreaittimes.com/news/articleView.html?idxno=157265"
  },
  "original_language": "en",
  "account": "Celltrion's infliximab biosimilar, Remsima, has claimed the top spot in Japan's infliximab market, marking an 11-year milestone since its introduction in the country. According to Celltrion, Remsima holds a 48% share of the infliximab market in Japan as of July, based on data from pharmaceutical market research firm IQVIA and local sources. This achievement marks the first time since its entry into the Japanese market in 2015 that Remsima has topped the market. Unlike in many other markets, where price differences play a significant role in biosimilar adoption, Japan's competitive landscape requires physicians' prescribing experience, accumulated clinical and real-world data, product familiarity, and pharmaceutical companies' sales capabilities to drive market share. Celltrion has successfully navigated Japan's market by partnering with local pharmaceutical company Nippon Kayaku for distribution and strengthening its direct sales efforts through its local subsidiary since late 2017. This strategy has helped build a prescription base and increased familiarity with the product among physicians. Celltrion's portfolio of infliximab biosimilars in Japan includes Remsima, adalimumab biosimilar Yuflyma, tocilizumab biosimilar Avtozma, and ustekinumab biosimilar Steqeyma. The company's broader portfolio could create commercial synergies by offering multiple treatment options within overlapping physician and hospital networks. In addition to Remsima's success, Celltrion has established a strong presence in Japan's oncology biosimilar market, with its trastuzumab biosimilar Herzuma holding a 78% market share and bevacizumab biosimilar Vegzelma capturing 64%. Looking ahead, Celltrion plans to launch Remsima SC, the subcutaneous formulation of infliximab, in Japan in 2027. The addition of a subcutaneous option to the existing intravenous formulation will provide physicians and patients with greater flexibility in administering infliximab treatment. In Europe, Remsima SC has expanded treatment options beyond the traditional IV-centered infliximab market, and a similar rollout in Japan could further bolster Celltrion's position in the biosimilar market. However, competition in Japan's biosimilar market remains intense, and maintaining Remsima's position will require continued accumulation of prescribing data, physician confidence, and a tailored commercial strategy to align with Japan's regulatory and reimbursement environment.",
  "summary": "Celltrion’s infliximab biosimilar Remsima has become the most prescribed infliximab product in Japan, 11 years after entering a market where biosimilars have traditionally faced limited price-driven incentives.According to Celltrion, Remsima captured a 48% share of Japan’s infliximab market in July,",
  "key_points": [
    "Celltrion's Remsima leads Japan's infliximab market with 48% share since 2015",
    "Remsima's success in Japan attributed to physicians' prescribing experience and sales capabilities",
    "Celltrion plans to launch subcutaneous Remsima SC in Japan in 2027"
  ],
  "editors_take": "Celltrion's achievement cements its position as a major player in Japan's biosimilar market, where accumulated clinical data, product familiarity, and strong sales capabilities drive market share rather than just price.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}